Abstract:This study aimed to compare the efficacy and safety of generic exenatide with branded exenatide Byetta® in Chinese patients with type 2 diabetes mellitus (T2DM) inadequately controlled on monotherapy or combination therapy of metformin and insulin secretagogues. A multicenter, randomized, controlled, non-inferiority trial was performed. A total of 240 patients with T2DM and glycated hemoglobin (HbA1c) ≥ 7% (53 mmol/mol) to ≤ 9.0% (75 mmol/mol) on monotherapy or combination therapy of metformin and insulin secretagogues for at least 3 months were randomized into generic exenatide or branded exenatide groups with a 1:1 ratio for 16 weeks of treatment. The primary endpoint was the change in HbA1c levels from baseline at week 16, with a non-inferiority margin of − 0.35% (− 3.83 mmol/mol) (lower bound of one-sided 95% confidence interval (CI) > − 0.35% (− 3.83 mmol/mol)). Secondary endpoints included the proportion of participants achieving HbA1c < 7% (53 mmol/mol), the changes in fasting plasma glucose (FPG), 2-h postprandial glucose (2hPG) following a standard meal, 7-point self-monitoring blood glucose (SMBG) profiles, body weight change from baseline at week 16 and the change in HbA1c levels from baseline at week 8. Safety issues were also evaluated. After 16 weeks of treatment, HbA1c levels decreased significantly from baseline in the two groups, with a reduction of − 1.10% ± 1.31% (− 12.0 mmol/mol ± 14.3 mmol/mol) in the generic exenatide group and − 1.08% ± 1.11% (− 11.8 mmol/mol ± 12.1 mmol/mol) in the branded exenatide group (both P < 0.001). The least-squares mean difference of HbA1c reduction between the two groups was − 0.03% (− 0.33 mmol/mol), with a lower one-sided 95% CI limit of − 0.27% (− 2.95 mmol/mol), which was higher than the prespecified non-inferiority margin of − 0.35% (− 3.83 mmol/mol). Moreover, there were no significant differences in the proportion of participants achieving HbA1c < 7% (53 mmol/mol) and the changes in FPG, 2hPG, 7-point SMBG profiles and body weight at week 16 and the change in HbA1c levels from baseline at week 8 (all P > 0.05) between the two groups. The incidence of adverse events, including the incidence of hypoglycemia (18.3% and 17.5%, respectively), was similar for the generic and branded exenatide groups (P > 0.05). In patients with T2DM inadequately controlled on monotherapy or combination therapy of metformin and insulin secretagogues, add-on treatment with generic exenatide demonstrated non-inferiority to branded exenatide in terms of improvements in HbA1c after 16 weeks of treatment. Furthermore, the two drugs were also similar for other efficacy endpoints and safety profile. Trial registration Chinese Clinical Trial Registry: ChiCTR-IPR-15006558, Date registered May 27, 2015.

Effects of Different Time Injection of Exenatide on Gastrointestinal Reactions in Patients with Type 2 Diabetes Millitus

Comparative effectiveness of metformin monotherapy in extended release and immediate release formulations for the treatment of type 2 diabetes in treatment-naïve Chinese patients: analysis of results from the CONSENT trial.

Clinical observation of "DM120 Decoction" for type 2 diabetes mellitus: A report of 30 cases

Impact of GLP-1 Receptor Agonists on Major Gastrointestinal Disorders for Type 2 Diabetes Mellitus: a Mixed Treatment Comparison Meta-Analysis.

The Clinical Efficiency of Exenatide-4 Type Ⅱ Diabetes

Efficacy and tolerability of exenatide monotherapy in obese patients with newly diagnosed type 2 diabetes: a randomized, 26 weeks metformin-controlled, parallel-group study.

Efficacy and safety of exenatide in Chinese patients with type 2 diabetes inadequately controlled with metformin or metformin and a sulfonylurea

Efficacy and safety of domestic exenatide injection in treating type 2 diabetes: A multicenter, randomized, controlled, and non-inferiority trial

Effect of Exenatide after Short-Time Intensive Insulin Therapy on Glycaemic Remission Maintenance in Type 2 Diabetes Patients: a Randomized Controlled Trial

Comparison of the Effects of Twice-Daily Exenatide and Insulin on Carotid Intima-Media Thickness in Type 2 Diabetes Mellitus Patients: a 52-Week Randomized, Open-Label, Controlled Trial

Efficacy and Safety of Exenatide in Patients of Asian Descent with Type 2 Diabetes Inadequately Controlled with Metformin or Metformin and a Sulphonylurea

Comparing the Effects of Twice-Daily Exenatide and Insulin on Renal Function in Patients with Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Controlled Trial.

Efficacy of Exenatide Administered Twice Daily in Body Mass Index Reduction in Patients with Type 2 Diabetes Mellitus

Association of Time in Range with Endothelial Injury in Patients with Type 2 Diabetes Treated with Exenatide

Comparison of Glycemic Variability in Chinese T2DM Patients Treated with Exenatide or Insulin Glargine: A Randomized Controlled Trial

Efficacy and Safety of Generic Exenatide Injection in Chinese Patients with Type 2 Diabetes: a Multicenter, Randomized, Controlled, Non-Inferiority Trial.

Effects of Exenatide Versus Insulin Glargine on Body Composition in Overweight and Obese T2DM Patients: a Randomized Controlled Trial

Pharmacokinetics, safety, and tolerability of single- and multiple-dose exenatide once weekly in Chinese patients with type 2 diabetes mellitus

Improved post-prandial ghrelin response by nateglinide or acarbose therapy contributes to glucose stability in Type 2 diabetic patients

Non-targeted Metabolomic Analysis Predicts the Therapeutic Effects of Exenatide on Endothelial Injury in Patients with Type 2 Diabetes.

966-P: Effect of Baseline SS-Cell Function on Treatment Response to Exenatide in Patients with Newly Diagnosed Type 2 Diabetes